Renalytix plc (NASDAQ: RNLX) (LSE: RENX) announces the publication of new real-world evidence (RWE) in Primary Care and Community Health demonstrating the Company’s KidneyIntelX bioprognostic™ test resulted in changed clinical decision making for patients in the early-stage of diabetic kidney disease (DKD) being cared for within the Mount Sinai Health System’s Population Health Ambulatory Pharmacy and Condition Management programs.
What about the kidneys make them a hotspot for COVID-19’s cytokine storm? A research team says it’s the presence of a protein found on specialized renal transport cells.
Now, as part of an effort to reduce the rate of patients with diabetic kidney disease who develop kidney failure, researchers at Penn Medicine are spearheading a collaboration to better understand the progression of DKD and advance research aimed at preserving kidney function in these patients.
Noninvasive measurement may provide alternative to diagnostic kidney biopsy Charlottesville, Va. (June 24, 2019)—Metabolomics, the study of small molecules the body produces during metabolism (metabolites) may be a future key to identifying diabetes-related kidney disease. The finding will be presented…